One of the nation’s most renowned pain experts, Dr. Edgar Ross, joins JanOne’s Scientific Advisory Board

June 30, 2020

Ross to play an instrumental role in the development of the company’s strategic plans to bring non-addictive pain medications to market Las Vegas, Nevada, June 30, 2020 – JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties announced... READ MORE

JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor

June 25, 2020

Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR LAS VEGAS, NV, June 25, 2020 - JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build a world-class... READ MORE

JanOne Launches Strategic Alternatives Process for Legacy Businesses

June 18, 2020

LAS VEGAS, June 18, 2020 – JanOne Inc. (Nasdaq:JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, today announced the commencement of a strategic alternative process for its legacy businesses in an effort to enhance shareholder value. This review process will be... READ MORE

JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development

February 6, 2020

JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020 LAS VEGAS, NV, February 6, 2020 - JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with... READ MORE

Amol Soin, MD, One Of The Nation’s Leading Pain Experts, Named As JanOne’s Chief Medical Officer

January 28, 2020

Soin brings extensive pain treatment and clinical experience to the JanOne team with particular expertise in pain associated with cardiovascular conditions Las Vegas, Nevada, January 28, 2020 – JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, announced... READ MORE

JanOne Scientific Advisory Board Chair And Leading Pain Expert Featured on ABC-7 WJLA America This Week

January 23, 2020

Dr. Christopher Kevil, pioneer in nitrite based PAD treatment and Dr. Amol Soin, foremost expert is neuropathic pain, provide scientific insight on the pain relieving qualities of JanOne’s lead drug candidate Interview to be distributed nationally on all 193 Sinclair broadcasting network affiliate stations in 89 markets across the nation. Las Vegas, Nevada, January 23,... READ MORE

Recent Data Paints Bleak Picture of the Cost of the U.S. Opioid Crisis

January 23, 2020

The opioid epidemic has had an intense impact on the nation. While it is difficult to deny the emotional toll endured by the families affected by opioid misuse, there are more tangible ways of measuring the issue. A recent release by NPR uncovered a startling amount of information about the actual financial cost of the... READ MORE

Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board

January 16, 2020

Kevil brings global scientific expertise to advance JanOne's drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will chair... READ MORE

Opioid Addiction: Men vs. Women

January 15, 2020

There’s no question that the opioid epidemic is running rampant and has to be stopped. There are many layers to this crisis; many of which leave people unable to fully comprehend its seriousness. In order to eradicate opioid misuse and the stigma surrounding drug addiction, we must do our part to raise awareness and present... READ MORE